HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Salar Selected Research

A Salar Research Topics

Disease

3Non-Hodgkin Lymphoma (Lymphosarcoma)
05/2021 - 02/2000
3Lymphoma (Lymphomas)
01/2018 - 02/2001
2Breast Neoplasms (Breast Cancer)
05/2021 - 07/2013
2Febrile Neutropenia
05/2021 - 07/2013
2Neutropenia
05/2021 - 07/2013
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
05/2016 - 02/2001
2B-Cell Lymphoma (Lymphoma, B Cell)
06/2014 - 07/2012
2Neoplasms (Cancer)
07/2013 - 10/2008
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
08/2003 - 07/2000
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
12/2021
1Thrombosis (Thrombus)
12/2021
1Splenic Rupture
12/2021
1Hemolysis
12/2021
1Evans Syndrome
12/2021
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
07/2020
1Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2016
1Fever (Fevers)
07/2013
1Fatigue
10/2008
1Hepatomegaly
05/2000
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2000

Drug/Important Bio-Agent (IBA)

2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
07/2013 - 07/2000
1Inosine Triphosphate (ITP)IBA
12/2021
1eltrombopagFDA Link
12/2021
1pegfilgrastim (Neulasta)FDA Link
05/2021
1Pharmaceutical PreparationsIBA
01/2018
1Cytarabine (Cytosar-U)FDA LinkGeneric
05/2016
1ChromatinIBA
06/2014
1Colony-Stimulating Factors (Colony Stimulating Factor)IBA
07/2013
1Rituximab (Mabthera)FDA Link
07/2012
1Darbepoetin alfa (Aranesp)FDA Link
10/2008
1Proteins (Proteins, Gene)FDA Link
10/2008
114-thioglycolamido-7,8-dihydromorphinone (TAMO)IBA
02/2001
1Tretinoin (Retinoic Acid)FDA LinkGeneric
05/2000
1IceIBA
03/2000
1IfosfamideFDA LinkGeneric
02/2000
1Etoposide (VP 16)FDA LinkGeneric
02/2000
1MethylprednisoloneFDA LinkGeneric
02/2000

Therapy/Procedure

6Drug Therapy (Chemotherapy)
05/2021 - 07/2000
2Therapeutics
05/2016 - 10/2008
1Salvage Therapy
07/2020
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
08/2003
1Stem Cell Transplantation
02/2001